New Treatment Approach Using Peptoid-Based Vaccines in Parkinson's Disease

As the population ages, the prevalence of neurodegenerative disease, such as Parkinson's disease (PD) continues to grow and new and alternative treatment modalities will be required to deal with these issues. Peptoids are oligomers of N-substituted glycine. These peptidomimetics molecules provide many advantages over peptide-based vaccines. Unlike peptides, peptoids are resistant to proteolytic degradation, and allow peptoids to retain therapeutic potential in some difficult physiological environments. Such molecules can also be engineered for structural stability and biomarker detection. All these elements make them suitable for a variety of applications in PD. Current research has investigated their potential to prevent protein aggregation, modulate cell signaling pathways and as anti-inflammatory agent for neuroprotective therapy. Expanding our understanding and applications of peptoids has great potential hope for future treatment options beyond current neurodegenerative disease options. This review will summarize the various applications peptoids, role in vaccination, potential for developing better prevention and treatment for PD.